Expression of HIF-1a and VEGF in human pituitary tumors and rodent pituitary tumor cell lines under hypoxia-mimicking condition

2008 ◽  
Vol 116 (09) ◽  
Author(s):  
B Shan ◽  
C Onofri ◽  
M Theodoropoulou ◽  
E Arzt ◽  
GK Stalla ◽  
...  
2007 ◽  
Vol 18 (1) ◽  
pp. 8-15 ◽  
Author(s):  
Takeo Minematsu ◽  
Noboru Egashira ◽  
Hanako Kajiya ◽  
Mao Takei ◽  
Susumu Takekoshi ◽  
...  

2017 ◽  
Vol 102 (10) ◽  
pp. 3692-3703 ◽  
Author(s):  
Shao Jian Lin ◽  
Ze Rui Wu ◽  
Lei Cao ◽  
Yong Zhang ◽  
Zhi Gen Leng ◽  
...  

Abstract Context The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas and other types of pituitary adenomas, but its clinical use is hampered by intolerance in some patients with prolactinoma and lack of effectiveness in other pituitary tumor types. Chloroquine (CQ) is an old drug widely used to treat malaria. Recent studies, including our own, have revealed that CAB and CQ are involved in induction of autophagy and activation of autophagic cell death. Objective To test whether CAB and CQ can function cooperatively to suppress growth of pituitary adenomas as well as other cancers. Results In vitro studies using the rat pituitary tumor cell lines MMQ and GH3, human pituitary tumor cell primary cultures, and several human cancer cell lines showed that CQ enhanced suppression of cell proliferation by CAB. These results were confirmed in in vivo xenograft models in nude mice and estrogen-induced rat prolactinomas. To understand the mechanism of combined CAB and CQ action, we established a low-CAB-dose condition in which CAB was able to induce autophagy but failed to suppress cell growth. Addition of CQ to low-dose CAB blocked normal autophagic cycles and induced apoptosis, evidenced by the further accumulation of p62/caspase-8/LC3-II. Conclusion The data suggest that combined use of CAB and CQ may increase clinical effectiveness in treatment of human pituitary adenomas, as well as other cancers, making it an attractive option in tumor and cancer therapies.


Endocrinology ◽  
2008 ◽  
Vol 149 (8) ◽  
pp. 4158-4167 ◽  
Author(s):  
Matthew Miller ◽  
Shenglin Chen ◽  
Jeffrey Woodliff ◽  
Sanjay Kansra

Prolactinomas are the most prevalent functional pituitary adenomas. Dopamine D2 receptor (D2R) agonists, such as bromocriptine are the first line of therapy; however, drug intolerance/resistance to D2R agonists exists. Apart from D2R agonists, there is no established medical therapy for prolactinomas; therefore, identifying novel therapeutics is warranted. Curcumin, a commonly used food additive in South Asian cooking, inhibits proliferation of several tumor cell lines; however, its effect on pituitary tumor cell proliferation has not been determined. Our objectives were to: 1) determine whether curcumin inhibits proliferation of pituitary tumor cell lines; 2) identify the signaling intermediaries that mediate the effect of curcumin; 3) examine whether curcumin inhibited pituitary hormone production and release; and 4) examine whether curcumin could enhance the growth-inhibitory effect of bromocriptine. Using rat lactotroph cell lines, GH3 and MMQ cells, we report that curcumin had a robust dose and time-dependent inhibitory effect on GH3 and MMQ cell proliferation. Inhibitory effects of curcumin persisted, even on removal of curcumin, and curcumin also blocked colony formation ability of pituitary tumor cells. The growth-inhibitory effect of curcumin was accompanied by decreased expression of cyclin D3 and ser 780 phosphorylation of retinoblastoma protein. In addition, curcumin also induced apoptosis in both GH3 and MMQ cells. Furthermore, curcumin suppresses intracellular levels and release of both prolactin and GH. Finally, we show that low concentrations of curcumin enhanced the growth-inhibitory effect of bromocriptine on MMQ cell proliferation. Taken together we demonstrate that curcumin inhibits pituitary tumor cell proliferation, induces apoptosis, and decreases hormone production and release, and thus, we propose developing curcumin as a novel therapeutic tool in the management of prolactinomas.


Endocrine ◽  
2008 ◽  
Vol 33 (1) ◽  
pp. 62-76 ◽  
Author(s):  
Katharina H. Ruebel ◽  
Alexey A. Leontovich ◽  
Yoshinori Tanizaki ◽  
Long Jin ◽  
Gail A. Stilling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document